Prognostic value of radiological response to chemotherapy in patients with osteosarcoma

PLoS One. 2013 Jul 29;8(7):e70015. doi: 10.1371/journal.pone.0070015. Print 2013.

Abstract

Background: Chemotherapy is essential to improve the prognosis of the patients with osteosarcoma, and the response to chemotherapy is an important prognostic factor. In this study, the impact of various radiological examinations on overall survival (OS) and event-free survival (EFS) was evaluated.

Method: Eighty-two patients with high-grade osteosarcoma were included in this study, and we evaluated the following factors for prognostic significance: age (≥40 years), gender (male), tumor location (truncal site), metastatic disease, histological response to chemotherapy, radiological response to chemotherapy assessed using X-ray, angiography, CT, MRI, (201)Tl scintigraphy, and (99m)Tc-MIBI scintigraphy ((99m)Tc-MIBI), and combined radiological score (CRS).

Results: Univariate analyses revealed that metastatic disease, histological response, (99m)Tc-MIBI, and CRS were significantly correlated with OS. Multivariate analyses showed that metastatic disease (OS: HR 35.9, P<0.001; EFS: HR 17.32, P<0.001) was an independent predictor of OS and EFS. Tumor location (HR 36.1, P = 0.003), histological response (HR 31.1, P = 0.036), and (99m)Tc-MIBI (HR 18.4, P = 0.038) were significant prognostic factors for OS. Moreover, CRS was a marginally significant predictor of OS and EFS.

Conclusion: The chemotherapeutic effects evaluated by (99m)Tc-MIBI and CRS could be considered as prognostic factors in osteosarcoma.

MeSH terms

  • Adult
  • Disease-Free Survival
  • Female
  • Humans
  • Male
  • Osteosarcoma / diagnostic imaging*
  • Osteosarcoma / drug therapy*
  • Osteosarcoma / mortality
  • Prognosis
  • Radionuclide Imaging
  • Technetium Tc 99m Sestamibi*
  • Treatment Outcome

Substances

  • Technetium Tc 99m Sestamibi

Grants and funding

The authors have no support or funding to report.